Spruce Biosciences Bolsters Leadership Ahead of Potential FDA Nod for Rare Disease Therapy

Event summary

  • Spruce Biosciences appointed Eric Jordan as VP of Marketing and Tina Gullotta as VP of Finance and Corporate Controller on June 15, 2026.
  • Jordan brings 20+ years of rare disease marketing experience, including leading the $1B launch of Oxervate at Dompé Pharmaceuticals.
  • Gullotta has 25+ years of finance leadership in biotech, with experience guiding companies through IPOs and commercial-stage transitions.
  • Both executives received inducement awards of 3,500 RSUs, vesting over four years.

The big picture

Spruce Biosciences is fortifying its leadership team as it approaches a critical inflection point: the potential FDA approval and commercial launch of TA-ERT. The appointments of Jordan and Gullotta signal the company's shift from clinical development to commercial execution, a pivotal transition for any biotech nearing regulatory milestones. With no approved therapies currently available for Sanfilippo Syndrome Type B, Spruce's success could position it as a key player in the rare disease space, though it must navigate competitive dynamics and execution risks.

What we're watching

Regulatory Timeline
The pace at which Spruce advances toward FDA approval for TA-ERT, its lead candidate for Sanfilippo Syndrome Type B.
Commercial Readiness
How effectively Jordan and Gullotta can build out marketing and finance infrastructure ahead of a potential launch.
Market Positioning
Whether Spruce can establish TA-ERT as the first disease-modifying treatment for MPS IIIB in a competitive rare disease landscape.